PCK3145 peptide is a synthetic PSP94-derived research compound studied in prostate cancer and bone metastasis. Learn its mechanism, status, and safety.
PCK3145 is a synthetic research peptide derived from human PSP94, a protein produced by prostate tissue. It was studied in laboratory work and early-phase clinical trials, mostly in prostate cancer and bone metastasis. PCK3145 is not an approved drug, is not sold as a supplement, and has no established human dose.
What Is the PCK3145 Peptide?
PCK3145 belongs to a group of short, laboratory-made peptides designed to mimic a small active region of a much larger natural protein. Its parent protein, PSP94 (also called beta-microseminoprotein), is abundant in seminal fluid and has been investigated for years as a biomarker in prostate disease.
Researchers describe PCK3145 as a fragment of PSP94 rather than a full protein. Small fragments are easier to synthesize, purify, and test in cell culture than full-length proteins, which makes them attractive starting points for drug discovery. For readers asking what is a peptide, the simple definition is a chain of amino acids shorter than a protein — and compounds like PCK3145 are engineered to interact with specific biological targets.
How Was PCK3145 Studied?
Preclinical work on PCK3145 centered on two areas: tumor biology and bone health. Both were explored in cell cultures and animal models, not in large human studies.
- Matrix metalloproteinase activity: PCK3145 was reported to reduce activity of MMP-9, an enzyme associated with tumor invasion and spread.
- Osteoclast signaling: Studies examined whether the peptide could blunt the bone-destroying activity of osteoclasts, which matters because prostate cancer frequently spreads to bone.
- Cell growth assays: Laboratory work looked at whether PSP94-derived fragments could slow the proliferation of prostate cancer cell lines.
These findings were preliminary. Results in cell cultures and animal models do not automatically translate into benefits for people, and PCK3145 never advanced far enough in trials to demonstrate a clinical benefit.
Clinical Trial History and Current Status
PCK3145 moved into Phase I and Phase II testing in the 2000s for castration-resistant prostate cancer, including patients with bone metastases. Those trials were small and designed mainly to assess safety, tolerability, and early signals rather than to prove a survival advantage. Development was later discontinued, and no PCK3145 product is marketed anywhere today.
PCK3145 is not FDA-approved, is not a prescription drug, and is not available as a dietary supplement in the United States.
Because the peptide was never approved, any product labeled "PCK3145" sold online is a research chemical. That status carries real risk: unknown purity, no manufacturing oversight, and no dose that can honestly be called safe or effective.
How PCK3145 Compares With Other Research Peptides
Peptide research spans everything from oncology compounds to cosmetic ingredients, and the evidence base varies enormously from one to the next.
| Peptide | Parent Source | Main Research Focus | Regulatory Status |
|---|---|---|---|
| PCK3145 | Fragment of human PSP94 protein | Prostate cancer and bone metastasis (early phase, discontinued) | Not approved for human use |
| Prostamax-type prostate blends | Non-standardized marketed blends | Prostate "support" marketing claims | Not approved; no recognized drug status |
| GV1001 | Telomerase-derived 16-amino-acid peptide | Cancer vaccine research, including pancreatic cancer | Not approved for any US indication |
| BPC-157 | Synthetic fragment of human gastric juice protein | Tissue repair research in animals | Not approved for human use |
Anyone comparing options quickly notices that the prostamax peptide and the gv1001 peptide sit at very different stages of evidence, and neither is an approved treatment. Evidence quality matters more than marketing language when you evaluate any research compound.
Safety, Legality, and What to Ask a Clinician
No human dosing schedule for PCK3145 has been established or approved by regulators. That single fact shapes every practical question about the compound.
- No approved dose: Without approved trials, there is no reference range for safety or effectiveness.
- No safety database: Long-term effects, drug interactions, and immune reactions are largely uncharacterized.
- No pharmacy safeguards: Research chemicals bypass the identity, sterility, and potency checks required of approved drugs.
- Legal gray areas: Status varies by state and by how a product is labeled and sold.
Peptide science is a sensitive topic in oncology. Conversations about peptides and cancer growth often blend genuine laboratory mechanisms with unproven marketing claims, and that blend can mislead patients who are genuinely looking for options. A lab result showing that a peptide changes one signaling pathway is not evidence that it treats cancer in people.
If you are considering any peptide therapy, including compounds marketed for body composition, speak with a licensed physician first. Coverage of peptides for weight loss side effects shows that even widely sold products can carry meaningful risks, and the same caution applies with even more force to unapproved oncology peptides.
Key Takeaways
- PCK3145 is a synthetic fragment of the PSP94 protein and is not an approved medicine.
- Early research focused on MMP-9 activity and bone metastasis, but clinical development was discontinued.
- No PCK3145 product is legally marketed for human use in the United States.
- Online listings for research peptides offer no guarantee of purity, identity, or sterility.
- Anyone considering peptide therapy should consult a licensed healthcare professional before using anything.
Frequently Asked Questions
Is PCK3145 available for human use?
No. PCK3145 is not FDA-approved for any indication, and no PCK3145 product is marketed as a medicine or supplement in the United States. Anything sold under that name online is a research chemical with no verified purity or dosing. There is no established safe or effective human dose.
What protein is PCK3145 derived from?
PCK3145 is a synthetic fragment of PSP94, also known as beta-microseminoprotein, a protein produced by prostate tissue. Researchers created the peptide to mimic a small active region of that larger protein. PSP94 itself has been studied mainly as a prostate-related biomarker.
Did PCK3145 clinical trials succeed?
PCK3145 reached Phase I and Phase II trials in the 2000s for castration-resistant prostate cancer, often in patients with bone metastases. Those trials were small and focused on safety and early signals rather than proven survival benefit. Development was discontinued, and the peptide never received approval.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.